• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi welcomes renewed commitment of GHIT Fund for Chagas disease research

Home > News

DNDi welcomes renewed commitment of GHIT Fund for Chagas disease research

Lab material
22 Apr 2020
  • English
    • English
    • 日本語

After supporting an early-stage research project for Chagas disease, the Global Health Innovative Technology (GHIT) Fund has announced its renewed commitment to fund the next steps of the collaborative project of DNDi and Daiichi Sankyo. The two partners are progressing a lead optimization project on promising compounds series – all of which were previously identified through a GHIT-supported screening venture – with the objective of developing a totally new, oral, safe, and effective treatment for people affected by Chagas disease.

The new funding of EUR 3.58 million (JPY 431.85 million) will support the two-year project, which aims to identify one optimized lead candidate for Chagas disease.

GHIT has been a DNDi supporter since 2013, supporting R&D projects for several neglected diseases in addition to Chagas disease, including visceral leishmaniasis, cutaneous leishmaniasis, and mycetoma. GHIT also supports innovative research mechanisms, such as DNDi’s NTD Drug Discovery Booster.

About Chagas disease

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the Trypanosoma cruzi parasite. About 6 to 7 million people worldwide are estimated to be infected mainly in Latin American countries where the disease is endemic.

Currently available treatments are more than 40 years old, and while they show good efficacy in the acute phase, they need to be used in long regimens and cause significant side effects. None of the existing treatments are safe to use during pregnancy, which is an important unmet medical need. The project aims to address these challenges.

More information

Read GHIT press release

Read Daiichi Sankyo CSR Activities News

Contact

media@dndi.org

Funding Chagas disease

Read, watch, share

Loading...
Publications
15 Jul 2025

DNDi 2024 Annual Report

Healthcare worker attending a training
Press releases
10 Jul 2025

New HIV project in the DRC brings life-saving care closer to people with advanced HIV disease

Woman working in a laboratory
News
10 Jul 2025

LEO Foundation partners with DNDi to develop breakthrough drug discovery model for mycetoma 

Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
10 Jun 2025

Bringing life-saving care closer to people living with HIV in Kinshasa 

News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License